Get started
Edesa Biotech, Inc.Edesa Biotech, Inc.Edesa Biotech, Inc.

Edesa Biotech, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

EDSA chart


Full chart

EDSA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪17.48 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.88 USD
Net income (FY)
‪−6.17 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪6.05 M‬
Beta (1Y)
0.19

Employees


Employees (FY)
16
Change (1Y)
0
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−385.63 K‬ USD

About Edesa Biotech, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pardeep Nijhawan
Website
edesabiotech.com
Headquarters
Markham
Founded
2007
FIGI
BBG000R0LC72
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EDSA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as EDSA.

Frequently Asked Questions


The current price of EDSA is 2.46 USD — it has decreased by −1.62% in the past 24 hours. Watch Edesa Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Edesa Biotech, Inc. stocks are traded under the ticker EDSA.
EDSA stock has fallen by −1.22% compared to the previous week, the month change is a 22.97% rise, over the last year Edesa Biotech, Inc. has showed a −43.07% decrease.
We've gathered analysts' opinions on Edesa Biotech, Inc. future price: according to them, EDSA price has a max estimate of 21.00 USD and a min estimate of 20.00 USD. Watch EDSA chart and read a more detailed Edesa Biotech, Inc. stock forecast: see what analysts think of Edesa Biotech, Inc. and suggest that you do with its stocks.
EDSA reached its all-time high on Aug 28, 2014 with the price of 6,934.24 USD, and its all-time low was 1.55 USD and was reached on Dec 20, 2024. View more price dynamics on EDSA chart.
See other stocks reaching their highest and lowest prices.
EDSA stock is 5.49% volatile and has beta coefficient of 0.19. Track Edesa Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is Edesa Biotech, Inc. there?
Today Edesa Biotech, Inc. has the market capitalization of ‪17.48 M‬, it has decreased by −2.01% over the last week.
Yes, you can track Edesa Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Edesa Biotech, Inc. is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
EDSA earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.31 USD resulting in a −54.84% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Edesa Biotech, Inc. earnings.
Edesa Biotech, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
EDSA net income for the last quarter is ‪−1.62 M‬ USD, while the quarter before that showed ‪−962.05 K‬ USD of net income which accounts for −68.10% change. Track more Edesa Biotech, Inc. financial stats to get the full picture.
No, EDSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 31, 2025, the company has 16 employees. See our rating of the largest employees — is Edesa Biotech, Inc. on this list?
Like other stocks, EDSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Edesa Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Edesa Biotech, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Edesa Biotech, Inc. stock shows the sell signal. See more of Edesa Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.